News

3B BlackBio Dx Limited, formerly Kilpest India Limited, announced that its shareholders approved the re-appointment of Mrs. Mithla Dubey, aged 79 years, at the company’s 54th Annual General Meeting held on September 29, 2026. Mrs. Dubey is the mother of Chairman cum Managing Director Mr. Dhirendra Dubey and Whole-Time Director cum CFO Mr. Nikhil Kuber Dubey, and her re-appointment fulfills the requirement for a woman director on the board as per applicable regulations.

Kilpest India Limited, now known as 3B BlackBio Dx Limited, informed the BSE Limited that the trading window for its securities will be closed for directors, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the public announcement of the unaudited financial results for the quarter and half-year ending September 30, 2026.

3B Blackbio DX Ltd share price gained 3.33% to Rs 1246.65. The Company`s net profit eased 8.37% to Rs 8.98 crore, while revenue from operations softened by 5.48% to Rs 33.49 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 73454.32 crore, improving 10.78%. It has inched up 3.04% over last one week and jumped by 15.68% in last one month while the market capitalization of 3B Blackbio DX Ltd has marginally improved by 3.54% and 9.16% in the same period respectively. Profit before tax (PBT) of 3B Blackbio DX Ltd stood at Rs 13.22 crore in Q2 FY26, nosediving by 16.65% year-on-year, and declining 9.76% quarter-on-quarter. EBITDA came in at Rs 2 crore, tanking 68.35% YoY and tumbling by 243.37% sequentially. Total expenses dropped by 14.66% to Rs 26.31 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.85 crore, inching up 8.13% YoY, while employee benefits expense was at Rs 8.55 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 30.15% to Rs 96.47 crore, while net profit soared by 48.57% to Rs 47.69 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1948% to Rs 35.03 crore, and PBT surged 44.37% to Rs 64.0 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 43.36 crore in FY26, as against Rs 26.95 crore in FY25. 3B Blackbio DX Ltd nosedived by 19.97% in last one year, underperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.

3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 13 August 2026.

3B Blackbio DX announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.